Effect of lenvatinib (E7080) on the QTc interval: results from a thorough QT study in healthy volunteers

Methodologies to characterize the QT/corrected QT interval in the presence of drug-induced heart rate changes or other autonomic effects

(2012) Christine E. Garnett et al.   AMERICAN HEART JOURNAL

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

(2012) D S Boss et al.   BRITISH JOURNAL OF CANCER

A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors

(2012) Thierry Lesimple et al.   INVESTIGATIONAL NEW DRUGS

Highly Automated QT Measurement Techniques in 7 Thorough QT Studies Implemented under ICH E14 Guidelines

(2011) Jean-Philippe Couderc et al.   ANNALS OF NONINVASIVE ELECTROCARDIOLOGY

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

(2011) K. Yamada et al.   CLINICAL CANCER RESEARCH

A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects

(2011) Richat Abbas et al.   INTERNATIONAL JOURNAL OF CANCER

Population Pharmacokinetic and Concentration-QTc Models for Moxifloxacin: Pooled Analysis of 20 Thorough QT Studies

(2011) Jeffry A. Florian et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer

(2010) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants

(2010) Sriram Krishnaswami et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Concentration-QT Relationships Play a Key Role in the Evaluation of Proarrhythmic Risk During Regulatory Review

(2007) Christin E. Garnett et al.   JOURNAL OF CLINICAL PHARMACOLOGY